Inflammatory Markers in Rheumatoid Patients and Cardiac Function: Insights from an Iranian University Hospital
Novelty in Biomedicine,
Vol. 12 No. 4 (2024),
28 September 2024
,
Page 137-141
https://doi.org/10.22037/nbm.v12i4.44989
Abstract
Background: Rheumatoid arthritis (RA) is a chronic autoimmune disorder associated with increased cardiovascular morbidity and mortality. This study investigated the association between RA inflammatory markers, such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and various cardiac function parameters.
Materials and Methods: A cross-sectional study involved 71 patients diagnosed with RA at Imam Hossein Hospital in Tehran, Iran. Cardiac function parameters, including left ventricular end-diastolic diameter (LVDD), left ventricular end-systolic diameter (LVDS), left ventricular ejection fraction (EF), E/A ratio, septal e' velocity, left atrial (LA) area, and LA size, were assessed using echocardiography. The correlation between RA inflammatory markers and cardiac function parameters was analyzed using Pearson correlation coefficients. Multiple linear regression models were employed to further explore these associations. Statistical analyses were performed using SPSS Statistics version 26.
Results: Among the cardiac function parameters assessed, only LA size significantly correlated with RA inflammatory markers (ESR-CRP) (p = 0.034). However, LVDD, LVDS, EF, and E/A ratios did not exhibit significant correlations. Septal e' velocity notably showed a weak positive correlation with inflammatory markers.
Conclusion: Our findings suggest a potential link between systemic inflammation in RA and cardiac remodeling, particularly affecting LA size. This highlights the importance of monitoring cardiac function parameters, especially LA size, in RA patients to identify individuals at higher risk of cardiovascular complications. Further research is warranted to elucidate this association's underlying mechanisms and clinical implications.
- Legg-Calve-Perthes Disease
- Orthopedics
- Pediatrics
- Pamidronate
How to Cite
References
Gravallese EM, Firestein GS. Rheumatoid arthritis—common origins, divergent mechanisms. New England Journal of Medicine. 2023;388(6):529-42.
Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Rheumatoid arthritis: advances in treatment strategies. Molecular and cellular biochemistry. 2023;478(1):69-88.
Black RJ, Cross M, Haile LM, et al. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023;5(10):e594-e610.
Weber BN, Giles JT, Liao KP. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nature Reviews Rheumatology. 2023;19(7):417-428.
Semb AG, Ikdahl E, Wibetoe G, Crowson C, Rollefstad S. Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis. Nature Reviews Rheumatology. 2020;16(7):361-79.
Kerola AM, Rollefstad S, Semb AG. Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and antirheumatic treatment. European Cardiology Review. 2021;16.
Wang M, Mei K, Chao C, et al. Rheumatoid arthritis increases the risk of heart failure-current evidence from genome-wide association studies. Frontiers in Endocrinology. 2023;14:1154271.
DeMizio DJ, Geraldino-Pardilla LB. Autoimmunity and inflammation link to cardiovascular disease risk in rheumatoid arthritis. Rheumatology and therapy. 2020;7(1):19-33.
Chen J, Norling LV, Cooper D. Cardiac dysfunction in rheumatoid arthritis: the role of inflammation. Cells. 2021;10(4):881.
Dhawan SS, Quyyumi AA. Rheumatoid arthritis and cardiovascular disease. Current atherosclerosis reports. 2008;10(2):128-33.
Siemons L, Ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA. How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC musculoskeletal disorders. 2014;15:1-7.
Shen R, Ren X, Jing R, et al. Rheumatoid factor, anti-cyclic citrullinated peptide antibody, C-reactive protein, and erythrocyte sedimentation rate for the clinical diagnosis of rheumatoid arthritis. Laboratory medicine. 2015;46(3):226-9.
Dessein PH, Joffe BI, Stanwix AE. High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. The Journal of rheumatology. 2004;31(6):1095-7.
Mokotedi L, Michel FS, Mogane C, et al. Associations of inflammatory markers with impaired left ventricular diastolic and systolic function in collagen-induced arthritis. PLoS One. 2020;15(3):e0230657.
Wu D, Luo Y, Li T, et al. Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Frontiers in Immunology. 2022;13:1051082.
Pope JE, Choy EH. C-reactive protein and implications in rheumatoid arthritis and associated comorbidities. Paper presented at: Seminars in arthritis and rheumatism. 2021.
Nikiphorou E, de Lusignan S, Mallen CD, et al. Cardiovascular risk factors and outcomes in early rheumatoid arthritis: a population-based study. Heart. 2020;106(20):1566-72.
Popescu D, Rezus E, Badescu MC, et al. Cardiovascular risk assessment in rheumatoid arthritis: accelerated atherosclerosis, new biomarkers, and the effects of biological therapy. Life. 2023;13(2):319.
Radu A-F, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857.
Ahlers MJ, Lowery BD, Farber‐Eger E, et al. Heart failure risk associated with rheumatoid arthritis–related chronic inflammation. Journal of the American Heart Association. 2020;9(10):e014661.
Akram M, Daniyal M, Sultana S, et al. Traditional and modern management strategies for rheumatoid arthritis. Clinica Chimica Acta. 2021;512:142-55.
- Abstract Viewed: 60 times
- pdf Downloaded: 41 times